Novel mechanisms involving chemically modified tetracycline 3 cytotoxicity

Publication Date

2014

Journal Title

Anticancer Drugs

Abstract

Chemically modified tetracycline 3 (CMT-3) is a potential anticancer drug because of its retained matrix metalloproteinases inhibitory property. In the present study, we showed that CMT-3 significantly inhibited the growth and proliferation of human hepatocellular carcinoma HepG(2) cells. Novel mechanisms including increased intracellular autophagy level and high-mobility group box 1 (HMGB1) release were involved. In addition, a major Danshen ingredient, tanshinone IIA sodium sulfonate (TSN-SS), significantly increased the cytotoxic effects of CMT-3 in HepG2 cells. Combining CMT-3 with TSN-SS led to enhanced accumulation of endogenous LC3-II, but reduced HMGB1 cytoplasmic translocation. Altogether, these findings suggest that autophagy and HMGB1 release may play important roles in the anticancer effect of CMT-3. As a novel candidate for cancer therapy, CMT-3 may be used in combination with TSN-SS, which possibly facilitates the execution of a death signal (e. g. autophagy) and prevents the survival of an inducer (e. g. HMGB1 cytoplasmic translocation), thus improving its therapeutic effect. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

Volume Number

25

Issue Number

10

Pages

1165-1174

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Emergency Medicine

PMID

27163120

DOI

10.1097/cad.0000000000000144

Comments

Hofstra Northwell School of Medicine and Northwell Health currently do not subscribe to this title. If you are an affiliate and would like to access the full text please request it via interlibrary loan via Hofstra Northwell School of Medicine ILL (faculty and students only) or Northwell Health ILL

This document is currently not available here.


Share

COinS